Study: NCT00196976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)